Spur Therapeutics (Ireland) LIMITED

Spur Therapeutics (Ireland) Limited is an Irish biotechnology company dedicated to advancing the practice of genetic medicine. By harnessing precise gene‑expression technologies and sophisticated delivery platforms, the firm develops transformational gene‑therapy candidates that aim to halt the progression of debilitating chronic conditions with a single dose of medicine.

The company’s flagship programme targets Gaucher disease, where it has already generated groundbreaking clinical data and presented its results at leading conferences such as WORLDSymposium™ and the ESGCT Annual Congress. Building on this success, Spur Therapeutics is expanding its pipeline to address more prevalent disorders, including specific forms of Parkinson’s disease, dementia and certain cardiovascular conditions. Their approach centres on delivering engineered variants of therapeutic enzymes—most notably an engineered GCase enzyme for Gaucher disease—through innovative gene‑therapy vectors.

Spur Therapeutics serves patients, clinicians and the broader research community by delivering cutting‑edge, disease‑modifying therapies that promise brighter futures. Their work is driven by a clear vision: to turn the promise of gene therapy into life‑changing reality for a growing number of people worldwide.